Systematic Financial Management LP Buys Shares of 181,390 Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Systematic Financial Management LP purchased 181,390 shares of Catalyst Pharmaceuticals, Inc. for approximately $4.4 million, representing around 0.15% ownership of the company.
• Insider Preethi Sundaram sold 2,324 shares at an average price of $26.41, reducing their position by 5.16%, while corporate insiders own about 10.40% of the company's stock.
• Catalyst Pharmaceuticals has received mixed ratings from analysts, with a consensus "Buy" rating and an average price target of $33.20.

Systematic Financial Management LP acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 181,390 shares of the biopharmaceutical company's stock, valued at approximately $4,399,000. Systematic Financial Management LP owned approximately 0.15% of Catalyst Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Cambridge Investment Research Advisors Inc. acquired a new position in Catalyst Pharmaceuticals during the first quarter worth $484,000. Principal Financial Group Inc. increased its holdings in Catalyst Pharmaceuticals by 2.8% during the first quarter. Principal Financial Group Inc. now owns 617,506 shares of the biopharmaceutical company's stock worth $14,975,000 after buying an additional 17,018 shares during the last quarter. Spire Wealth Management increased its holdings in Catalyst Pharmaceuticals by 27.7% during the first quarter. Spire Wealth Management now owns 18,429 shares of the biopharmaceutical company's stock worth $447,000 after buying an additional 4,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Catalyst Pharmaceuticals by 65.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 35,334 shares of the biopharmaceutical company's stock worth $857,000 after buying an additional 13,915 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in Catalyst Pharmaceuticals during the first quarter worth $2,343,000. Institutional investors own 79.22% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on CPRX shares. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Finally, Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Saturday, August 9th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $33.20.

Catalyst Pharmaceuticals Stock Up 0.6%

Shares of CPRX stock traded up $0.13 on Friday, reaching $20.51. The company had a trading volume of 248,455 shares, compared to its average volume of 1,307,433. The stock has a market capitalization of $2.51 billion, a PE ratio of 12.44, a price-to-earnings-growth ratio of 0.82 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a one year low of $19.00 and a one year high of $26.58. The business's 50-day moving average is $21.06 and its 200 day moving average is $22.53.

Insider Activity at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 26,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $20.20, for a total value of $525,200.00. Following the completion of the transaction, the director owned 379,620 shares in the company, valued at $7,668,324. This trade represents a 6.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Preethi Sundaram sold 2,324 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total transaction of $61,376.84. Following the completion of the transaction, the insider owned 42,681 shares of the company's stock, valued at approximately $1,127,205.21. This trade represents a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 167,894 shares of company stock worth $3,434,690 over the last three months. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.